Versartis (VSAR) Earning Somewhat Favorable Press Coverage, Report Finds
News stories about Versartis (NASDAQ:VSAR) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Versartis earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.1913434823272 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research firms have recently weighed in on VSAR. Cantor Fitzgerald set a $14.00 price objective on shares of Versartis and gave the stock a “buy” rating in a research note on Friday, October 27th. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research note on Sunday, January 21st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $5.63.
Shares of Versartis (VSAR) traded up $0.10 during trading hours on Tuesday, hitting $1.80. 333,800 shares of the company’s stock were exchanged, compared to its average volume of 615,956. Versartis has a 1 year low of $1.60 and a 1 year high of $24.00. The firm has a market cap of $60.88, a price-to-earnings ratio of -0.46 and a beta of 2.11. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/versartis-vsar-earning-somewhat-favorable-press-coverage-report-finds.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.